News Non-profit DNDi preps phase 3 trials for dengue antibody Non-profit DNDi has licensed a dengue therapy from India's SII, paving the way for a phase 3 trial in Malaysia, Thailand, and Brazil.
News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.